Auditors
Our statutory auditor is Ernst & Young AB, with Jonatan Hansson as the main responsible partner.
At the annual general meeting on 8 May 2025, Ernst & Young AB was re-elected as auditor for a period of one year.
Our statutory auditor is Ernst & Young AB, with Jonatan Hansson as the main responsible partner.
At the annual general meeting on 8 May 2025, Ernst & Young AB was re-elected as auditor for a period of one year.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.